13 13 2 MEDLINE 2001 13 (1) 2002 1) 1996 1997 56,108 50,086 89.3%
5.2% 2002 2) 1998 6 9,471 4,035 42.6% 17,301 8,527 8,774 16.2% 17.3% 10 60 11.7% 19.8% 60 Okuda 2003 3) 10,920 12 3,370 390 28 2001 4 7 5,836 54 53.7% 3,528 1 5 1,430 2 7 878 5,598 51.5% 2 2 4 2 4 17.3%
19.4% 100% 12.2% 60 79 20 49 62.5%54.1% 82% 2002 4) 3) population study 2003 5) 1998 1999 4 5 2 3 4 3 D (Definite) P (Possible) N (Negative) 2 1 D D P 1998 585 51.1% 1999 328 28.7%1998 D 27.2% P 30.1% N 37.6% 1999 33.2% 29.2% 34.7% 2 139 50 89 U 2003 6,7) 4 2001 11 12 4 10,123
100 200 20 65 6,857 68.3% 6,707 66.3% 4 2,201 32.8% 31.3% 28.9% 37.8% 36.8% 1,029 15.4% 611 9.2% 23.1% 22.4% 29.0% 26.5% EC PM2.5 SPM 3 EC PM2.5 SPM NOx 2 3 (2) IgE Ozasa 2002 8) 1995 2001 5 6 407 510 80.5 87.0% IgE IgE 1.5 IU/ml 3 4 3 13.8 22.9% 1.5 IU/ml 39.0 50.1% 15.0 IU/ml 11.4 23.2% <0.35, 1.50-2.99, 3.0-14.9 IU/ml
Okawa 2003 9) 1995 6 1,560 647 913 11 15 292 IgE 1996 6 1995 135 1999, 2000, 2001 1995 IgE IgE 40 2001 IgE 60 IgE 10 1995 40 IgE CAP RAST 2 6 16.1% IgE IgE (3) 2003 6,7) 4 797 408 389 356 103 338 714 PM2.5 533 278 255 PM2.5 SPM TSP 11 12 PM2.5 SPM TSP EC 13-16 4 2 17 PM2.5 SPM TSP EC 3.1 3.4
2.2 1.5 1.6 Nakamura 2003 10) 408 1) 2) 45 12 206 ±45.5±20.7 145 43.4±17.3 IgE eosinophil peroxidase (EPO) interleukin-4 recepter α-chain (IL4RA) 206 IgE 75 EPO Pro358Leu IL4RA Ile50Val Glu357Ala EPO Pro358Leu IgE IL4RA Ile50Val Glu357Ala IgE IgE 10 EPO Pro358Leu IL4RA Ile50Val Glu357Ala Ile50Val Glu357Ala EPO IL4RA EPO Pro358Leu 131 14 (4) 2002 11) 1988 1996 5
7 1995 18 r = 0.383, r = 0.402 r = 0.233 11 4 5 60 80% 1 (5) QOL (Quality of life) 2003 12) 2001 5 IgE QOL (Quality of life) 15 4 QOL 12 465 378 15 304 IgE 271 QOL IgE 19 8.49 1.37 QOL 2002 13) QOL health related QOL: HRQOL 2 Juniper rhinoconjunctivitis quality of life questionnaire: RQLQ SF-36 36 8
1998 3 1999 4 SF-36 QOL 8 QOL QOL QOL 2003 14) Juniper rhinoconjunctivitis quality of life questionnaire: RQLQ AR QOL JRQLQ No1 QOL 3 5 20 228 2002 99 119 10 40.2 ± 15.2 20 49 90% 88% 72% 73% (6) 2003 7) Mitakakis 2000 15) New South Wales (NSW)9 33 Personal Air Samplers Nasal Air Samplers 1 1 4 Alternaria spores, Cladosporium spores, 0 0.38 21 Alternaria spore 1 794 spores/hr 11 Cladosporium spores 0 396 spores/hr 4, 0 81 grains/hr 1 0 72 grains/hr 5
2002 16) PVDF 2002 17) IS 1993 13 IgE 2 2) 17,301 42.6% 16.2%Okuda 3) 10,920 5,598 51.5% 17.3% 19.4% 12.2%
4 6,7) 68.3% IgE Ozasa 8) 80.5 87.0% 7) Nakamura 10) 533 408 11) QOL 12-14) 7) 3 (1) 14, 15
(2) a. QOL b. IgE IgE c. 3
13 IgE
1),,, 51: 15-19, 2002. 2),,,, 105: 215-224, 2002. 3) Okuda M.: Epidemiology of Japanese cedar pollinosis throughout Japan. Ann Allergy Asthma Immunol 91:288-296, 2003. 4) 4093: 17-24, 2002. 5),,,, 21:64-65, 2003. 6) 2003. 7) 2003. 8) Ozasa K, Dejima K, Takenaka H: Prevalence of Japanese cedar pollinosis among schoolchildren in Japan. Int Arch Allergy Immunol 128:165-167, 2002. 9) Okawa T, Konnno A, Yamakoshi T, Numata T, Terada N, Shima M: Analysis of natural history of Japanese cedar pollinosis. Int Arch Allergy Immunol 131:39-45, 2003. 10) Nakamura H, Miyagawa K, Ogino K, Endo T, Imai T, Ozasa K, Motohashi Y, Matsuzaki I, Sasahara S, Hatta, Eboshida A. High contribution contrast between the genes of eosinophil peroxidase and IL-4 receptor -chain in Japanese cedar pollinosis. L Allergy Clin Immunol 112: 1127-1131, 2003. 11),,,,,,,,
49: 631-642, 2002. 12),,,,,,,, QOL 50 (7):1-7, 2003. 13) QOL 200: 407-410, 2002. 14),,,,,,,,,,,,, CrawfordBruce QOL (2002 ) 52 (Suppl.1): 21-56, 2003. 15) Mitakakis TZ, Tovey ER, Xuan W, Marks GB: Personal exposure to allergenic pollen and mould spores in inland New South Wales, Australia. Clin Exp Allergy 30:1733-1739, 2000. 16),, (Cry j 1, Dac g) 51: 609-614, 2002. 17) 200: 353-357, 2002.